Type Condition

Clemmons, NC

214 Clinical Trials near Clemmons, NC

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

EDP-938 for Respiratory Syncytial Virus

Winston-Salem, North Carolina
This trial tests an oral medication called EDP-938 for adults with RSV who are at high risk of severe illness. The goal is to help fight the virus or reduce its impact.

Trial Details

Trial Status:Recruiting

180 Participants Needed

Berzosertib + Standard Chemotherapy for Lung Cancer

Clemmons, North Carolina
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung cancer that has spared to other placed in the body (advanced). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving berzosertib together with carboplatin, gemcitabine, and pembrolizumab may work better in treating patients with squamous cell non-small cell lung cancer compared to carboplatin, gemcitabine, and pembrolizumab alone.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

12 Participants Needed

SG2501 for Blood Cancers and Lymphoma

Winston-Salem, North Carolina
This trial is testing a new drug called SG2501 to see if it is safe and effective for patients with certain blood cancers that have come back or did not respond to previous treatments. The study will find the best dose and check if the drug can help the immune system fight the cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting

72 Participants Needed

Copanlisib + Usual Treatment for Advanced Breast Cancer

Clemmons, North Carolina
This phase I trial studies the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2 negative breast cancer that has spread from where it first started (breast) to other places in the body (metastatic). Some breast cancer cells have receptors for the hormones estrogen or progesterone. These cells are hormone receptor positive and they need estrogen or progesterone to grow. This can affect how the cancer is treated. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Abemaciclib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding copanlisib to the usual therapy of fulvestrant and abemaciclib may work better than giving fulvestrant and abemaciclib alone in treating patients with breast cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

24 Participants Needed

CC-92328 for Multiple Myeloma

Winston-Salem, North Carolina
This trial is testing a new drug called CC-92328 to see if it is safe and effective for patients with multiple myeloma that has come back or didn't respond to other treatments. The study will see if the drug can slow down or stop the cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

70 Participants Needed

Donanemab for Alzheimer's Disease

Winston-Salem, North Carolina
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:65 - 80

2196 Participants Needed

MR-100A-01 for Birth Control

Winston-Salem, North Carolina
This trial is studying a birth control patch called MR-100A-01 in women. The patch contains hormones that prevent pregnancy by stopping ovulation and making it harder for sperm to reach eggs. The study will look at how well the patch works, how it affects menstrual cycles, and its safety and tolerability. The MR-100A-01 patch is similar to other transdermal contraceptive patches that have been studied for their effectiveness in preventing ovulation and controlling menstrual cycles.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:16 - 35
Sex:Female

1321 Participants Needed

Blood Clot Treatments for Stroke

Winston-Salem, North Carolina
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

514 Participants Needed

Immune System Booster for Non-Hodgkin's Lymphoma

Winston-Salem, North Carolina
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 following the treatment with CD19 CAR-T cell therapy may work better in treating large B-cell lymphoma than either drug alone.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

400 Participants Needed

Rocatinlimab for Eczema

Winston-Salem, North Carolina
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

769 Participants Needed

Upadacitinib for Giant Cell Arteritis

Winston-Salem, North Carolina
This trial tests if upadacitinib, combined with reducing steroid doses, helps people with giant cell arteritis achieve and maintain remission by reducing inflammation. Upadacitinib has been approved for the treatment of rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis, and is under investigation for other conditions.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50+

429 Participants Needed

BOTOX Injections for Essential Tremor

Winston-Salem, North Carolina
This trial is testing if BOTOX can help reduce arm shaking in adults with essential tremor. Participants will receive BOTOX injections over several cycles. The study will check for safety and effectiveness through medical assessments and questionnaires. Botulinum toxin type A (BOTOX) has been found effective in treating various movement disorders, including essential tremor, in previous studies.

Trial Details

Trial Status:Active Not Recruiting

174 Participants Needed

HZN-825 for Idiopathic Pulmonary Fibrosis

Winston-Salem, North Carolina
This trial tests HZN-825, a new oral medicine, in people with Idiopathic Pulmonary Fibrosis (IPF). The goal is to see if it can help by blocking a receptor that causes lung scarring. The study will check its safety and effectiveness over several months.

Trial Details

Trial Status:Active Not Recruiting

153 Participants Needed

Rucaparib for Non-Small Cell Lung Cancer

Winston-Salem, North Carolina
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

64 Participants Needed

LX9211 for Diabetic Neuropathy

Winston-Salem, North Carolina
This trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.

Trial Details

Trial Status:Active Not Recruiting

416 Participants Needed

VTX958 for Crohn's Disease

Winston-Salem, North Carolina
This trial is testing a new medication called VTX958 to help people with moderate to severe Crohn's Disease. The goal is to see if it can reduce inflammation in the intestines and improve symptoms. The study will involve several phases over a period of up to three years.

Trial Details

Trial Status:Active Not Recruiting

132 Participants Needed

IW-3300 for Interstitial Cystitis

Winston-Salem, North Carolina
This trial is testing a new drug called IW-3300 to see if it can help people with chronic bladder pain. The drug is given as a rectal foam and aims to relieve symptoms like pain, burning, and pressure. Patients will use the drug at home for a few months.

Trial Details

Trial Status:Active Not Recruiting

98 Participants Needed

BOTOX Injections for Bladder Pain Syndrome

Winston-Salem, North Carolina
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by lower urinary tract symptoms (LUTS). This study will assess how safe and effective BOTOX (onabotulinumtoxinA) is in treating IC/BPS. Adverse events and change in disease symptoms will be evaluated. BOTOX (onabotulinumtoxinA) is an investigational drug being developed for the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Study doctors randomly assign the participants to 1 of 2 groups, called treatment arms, to receive BOTOX or placebo. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 80 female participants, aged 18 to 75 years, with a diagnosis of IC/BPS will be enrolled in approximately 40 sites in the United States and Canada. Participants will receive BOTOX or placebo injected into the bladder on Day 1 and will be followed for at least 12 weeks in treatment 1. Eligible participants may request additional dose of BOTOX between Weeks 12 and 24, and will be followed for 12 weeks in treatment period 2. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Trial Details

Trial Status:Active Not Recruiting
Sex:Female

83 Participants Needed

V117957 for Interstitial Cystitis

Winston-Salem, North Carolina
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.

Trial Details

Trial Status:Active Not Recruiting
Sex:Female

44 Participants Needed

VIA Disc NP Allograft for Degenerative Disc Disease

Winston-Salem, North Carolina
This trial tests VIA Disc NP, an injection to repair damaged spinal discs, in adults aged 65+ with back pain not relieved by other treatments. The injection adds material to the damaged discs to improve function and reduce pain.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:65 - 80

21 Participants Needed

Why Other Patients Applied

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

SCS vs Conventional Management for Chronic Pain

Winston-Salem, North Carolina
To evaluate the safety and effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities compared to Conventional Medical Management (CMM) in patients with chronic low back and/or leg pain who have not undergone spinal surgery when using the Boston Scientific WaveWriter SCS Systems.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:22+

241 Participants Needed

EYE103 for Diabetic Macular Edema

Winston-Salem, North Carolina
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

960 Participants Needed

EYP-1901 for Age-Related Macular Degeneration

Winston Salem, North Carolina
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+

400 Participants Needed

EYE103 for Diabetic Macular Edema

Winston-Salem, North Carolina
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

960 Participants Needed

TAK-279 for Psoriasis

Winston-Salem, North Carolina
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1300 Participants Needed

RSV Vaccine for Adults 60+

Winston-Salem, North Carolina
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:60+

15500 Participants Needed

BI 690517 + Empagliflozin for Chronic Kidney Disease

Winston-Salem, North Carolina
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart disease. This study has 2 parts. In the first part, participants get empagliflozin or placebo matching BI 690517 for at least 6 weeks. Participants continue taking ACEi or ARB throughout the study if such treatments are indicated. In the second part, participants are divided into 2 groups by chance. One group takes BI 690517 tablets and the other group takes placebo tablets. Placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants take 1 tablet once a day in addition to empagliflozin for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 4 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

11000 Participants Needed

Cladribine for Myasthenia Gravis

Winston-Salem, North Carolina
The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

240 Participants Needed

COVID-19 Vaccine + RSV Vaccine for Adults 50+

Winston-Salem, North Carolina
This study will assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+

842 Participants Needed

Plozasiran for High Triglycerides

Winston-Salem, North Carolina
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1328 Participants Needed

1...678

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Clemmons, NC pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Clemmons, NC work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Clemmons, NC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Clemmons, NC is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Clemmons, NC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Clemmons, NC?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Clemmons, NC?

Most recently, we added EYE103 for Diabetic Macular Edema, Cross Linking for Corneal Transplant and Rituximab vs Mosunetuzumab for Follicular Lymphoma to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in North Carolina

Anxiety Clinical Trials in North Carolina

Schizophrenia Clinical Trials in North Carolina

ADHD Clinical Trials in North Carolina

Bipolar Disorder Clinical Trials in North Carolina

Multiple Sclerosis Clinical Trials in North Carolina

Autism Clinical Trials in North Carolina

Treatment Resistant Depression Clinical Trials in North Carolina

Borderline Personality Disorder Clinical Trials in North Carolina

Social Anxiety Disorder Clinical Trials in North Carolina

Parkinson's Disease Clinical Trials in North Carolina

Alzheimer's Disease Clinical Trials in North Carolina

By Location

Clinical Trials near Durham, NC

Clinical Trials near Charlotte, NC

Clinical Trials near Winston-Salem, NC

Clinical Trials near Chapel Hill, NC

Clinical Trials near Raleigh, NC

Clinical Trials near Asheville, NC

Clinical Trials near Greensboro, NC

Clinical Trials near Greenville, NC

Clinical Trials near Wilmington, NC

Clinical Trials near High Point, NC

Clinical Trials near Goldsboro, NC

Clinical Trials near Hickory, NC

Other People Viewed

By Subject

Top Clinical Trials near Kernersville, NC

Top Clinical Trials near Kannapolis, NC

Top Clinical Trials near Jacksonville, NC

Top Clinical Trials near Henderson, NC

Top Clinical Trials near Hillsborough, NC

Top Clinical Trials near Garner, NC

Top Clinical Trials near Davidson, NC

Top Clinical Trials near Cary, NC

Top Clinical Trials near Clyde, NC

Top Clinical Trials near Asheville, NC

Top Clinical Trials near Durham, NC

Top Clinical Trials near Fayetteville, NC

By Trial

Trichuris trichiura Eggs for Whipworm Infection

Electronic Decision Tool for Genetic Testing Decisions in Adolescents

Smoking Cessation for Tobacco-Related Cancer Prevention

CHORUS+ Program for Opioid Use Disorder

Pharmacist-Led Access to Medications for Opioid Use Disorder

BE-101 for Hemophilia B

BR-AM for Diabetic Foot Ulcer

Surgery for Early-Stage Breast Cancer

Cognitive Behavioral Therapy for Leukemia and Lymphoma-related Fatigue

Lenalidomide + Dexamethasone +/- Thalidomide for Multiple Myeloma

Parenting Programs for Preschoolers' Mental Health Issues

Immunotherapy + Adoptive Cell Therapy for Melanoma

Related Searches

Top Clinical Trials near Clinton, SC

Top Clinical Trials near Clyde, NC

Therapeutic Socks for Diabetic Neuropathy

Digital Culinary Medicine for Cancer

Barzolvolimab for Eczema

CAR-T Cell Therapy for Non-Hodgkin's Lymphoma

Brain Stimulation for Post-Concussion Syndrome

Talazoparib for Leukemia

Ketamine for Depression

Remote Ischemic Conditioning for Limited Mobility

Walking Program for Parkinson's Disease

Protein Intake for Aging Muscle Growth

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial